Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - quetiapine - prolonged-release tablet - 50 milligram(s) - diazepines, oxazepines, thiazepines and oxepines; quetiapine

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - quetiapine fumarate - prolonged-release tablet - 300 milligram(s) - diazepines, oxazepines, thiazepines and oxepines; quetiapine

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - quetiapine - prolonged-release tablet - 200 milligram(s) - diazepines, oxazepines, thiazepines and oxepines; quetiapine

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - quetiapine - prolonged-release tablet - 400 milligram(s) - diazepines, oxazepines, thiazepines and oxepines; quetiapine

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - quetiapine fumarate, quantity: 115.13 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; calcium hydrogen phosphate dihydrate; iron oxide yellow; sodium starch glycollate type a; silicon dioxide; povidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 4000 - quetiapine sandoz is indicated for:,bipolar disorder adults ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder (see dose and method of administration) ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years ? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years) ? treatment of schizophrenia

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - quetiapine fumarate, quantity: 345.39 mg (equivalent: quetiapine, qty 300 mg) - tablet, film coated - excipient ingredients: povidone; calcium hydrogen phosphate dihydrate; silicon dioxide; lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a; titanium dioxide; hypromellose; macrogol 4000 - quetiapine sandoz is indicated for:,bipolar disorder adults ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder (see dose and method of administration) ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years ? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years) ? treatment of schizophrenia

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - quetiapine fumarate, quantity: 28.78 mg (equivalent: quetiapine, qty 25 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; silicon dioxide; iron oxide yellow; sodium starch glycollate type a; povidone; magnesium stearate; iron oxide red; calcium hydrogen phosphate dihydrate; titanium dioxide; hypromellose; macrogol 4000 - quetiapine sandoz is indicated for:,bipolar disorder adults ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder (see dose and method of administration) ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years ? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years) ? treatment of schizophrenia

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - quetiapine fumarate, quantity: 230.26 mg (equivalent: quetiapine, qty 200 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; microcrystalline cellulose; lactose monohydrate; magnesium stearate; silicon dioxide; povidone; calcium hydrogen phosphate dihydrate; titanium dioxide; hypromellose; macrogol 4000 - quetiapine sandoz is indicated for:,bipolar disorder adults ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder (see dose and method of administration) ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years ? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years) ? treatment of schizophrenia

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - quetiapine fumarate, quantity: 230.284 mg (equivalent: quetiapine, qty 200 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; sodium starch glycollate type a; magnesium stearate; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; macrogol 400 - quetiapine rbx tablets are indicated for: bipolar disorder = maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes = treatment of depressive episodes associated with bipolar disorder (see dosage and administration) = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate schizophrenia = treatment of schizophrenia

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - quetiapine fumarate, quantity: 28.785 mg (equivalent: quetiapine, qty 25 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; calcium hydrogen phosphate dihydrate; povidone; sodium starch glycollate type a; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 400 - quetiapine rbx tablets are indicated for: bipolar disorder = maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes = treatment of depressive episodes associated with bipolar disorder (see dosage and administration) = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate schizophrenia = treatment of schizophrenia